Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
27/06/2024 12:38
June 27 (Reuters) - Silence Therapeutics PLC SLNCF.PK :
* SILENCE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM
ONGOING
SANRECO PHASE 1 STUDY OF DIVESIRAN IN POLYCYTHEMIA VERA PATIENTS
* SILENCE THERAPEUTICS: DIVESIRAN ELIMINATED NEED FOR
PHLEBOTOMY
IN ALL WELL-CONTROLLED PATIENTS FOLLOWING INFREQUENT DOSING
* SILENCE THERAPEUTICS PLC: DIVESIRAN WAS WELL TOLERATED
Source text for Eikon: ID:nBw6gWR1pa
Further company coverage: SLNCF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing